Status:
ACTIVE_NOT_RECRUITING
Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
Lead Sponsor:
Ipsen
Conditions:
Advanced or Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2...
Eligibility Criteria
Inclusion
- Males or females aged 18 years and older
- Patients scheduled to receive Cabometyx® in monotherapy or in combination with nivolumabfor advanced or metastatic renal cell carcinoma
- Decision to treat patients with Cabometyx® in monotherapy or in combination with nivolumab has to be taken prior to and independent from participation in the clinical study
- Provision of written informed consent
Exclusion
- Participation in another interventional clinical study at the same time
- Previous participation in this clinical study
Key Trial Info
Start Date :
March 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04106349
Start Date
March 3 2020
End Date
March 31 2027
Last Update
December 30 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Onze-Lieve-vrouw Ziekenhuis Aalst
Aalst, Belgium, 9300
2
Imeldaziekenhuis
Bonheiden, Belgium, 2820
3
Clinique Saint-Luc Bouge
Bouge, Belgium, 5004
4
AZ Sint-Jan Brugge
Bruges, Belgium, 8000